JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
A phase 1/2 trial of Glecirasib, Cetuximab in colorectal cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.
Overview
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05194995 by Allist Pharmaceuticals, Inc., with 48 participants enrolled, started 2022-02-17 and due to reach its primary completion in 2025-04-30. Interventions recorded: JAB-21822, Cetuximab. Conditions listed: Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
- TrialA Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- TrialA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
- TrialPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Shares Glecirasib, Shanghai Allist Pharmaceuticals, Colorectal cancer.
- TrialJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Shares Cetuximab, Colorectal cancer.
- PersonDongsheng Tu
Shares Cetuximab, Colorectal cancer.
- PersonCarsten Bokemeyer
Shares Cetuximab, Colorectal cancer.